Printed as of 12/17/2025

#### **Disclosures**

Personal Commercial (9
------------------------

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Akcea	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Amgen Inc.	Other - Fellowship support	Significant (>= \$5,000)	Prevention
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
BMS-Pfizer	Research/Research Grants	Modest (< \$5,000)	
Boeringer-Ingelheim	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Johnson & Johnson	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Novo Nordisk Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Roche Diagnostics	Research/Research Grants	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Takeda Pharmaceuticals North America, Inc	Research/Research Grants	Modest (< \$5,000)	Heart Failure and Cardiomyopathies

## Additional Personal Commercial Disclosures for Education Activities (1)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
CHFS	Other - Organizing committee	Modest (< \$5,000)	Heart Failure and Cardiomyopathies

## Personal Organizational or Other Non-Commercial (6)

Non-Commercial Enity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Alberta Innovates Health Solution Clincian Scientist Fellowship † Alberta Innovates Health Solution	Research/Research Grants	Significant (>= \$5,000)	General Cardiology Heart Failure and Cardiomyopathies
AREA19	Other - Board of advisors	None (\$0)	Other
Canadian Cardiovascular Society Bayer Vascular Award † Canadian Cardiovascular Society	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
European Society of Cardiology † European Society of Cardiology Young Investigator fellowship	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
FrontRX	Ownership Interest/Partnership/Principal	Modest (< \$5,000)	Other
Heart Failure Society of America Young Investigator grant † Heart Failure Society of America	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies

# Clinical Trial Enroller (3)

Trial Name	Trial Sponsor	Trial Funding Source
HEART-FID	American Regent	
DAPA-AHF	AstraZeneca Pharmaceuticals	
EMPACT-MI	Boehringer Ingelheim Pharmaceuticals, Inc	

## Institutional Financial Decision-Making Role (0)

No disclosures on record

# Expert Witness Testimony (0)

No disclosures on record

#### **Agreement**

Certified Education Attestation | Signed on 10/11/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/11/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

**Embargo** | Signed on 10/11/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 10/11/2023

#### **ACC** and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.